Fast-tracked skin cancer drug pembrolizumab gets approval

BBC report that a new drug for advanced skin cancer should be made available on the NHS in England, experts recommend. 

The National Institute for Health and Care Excellence says pembrolizumab is cost-effective to use in patients who have already tried not benefited from another drug called ipilimumab.  The treatment is considered a "next generation" drug in cancer care, stimulating the body's immune system to fight the disease. 

For further information visit the BBC website.

This is continuing evidence of the amount of research being undertaken in this area of medicine.  

 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
Gorlin Syndrome community on HealthUnlocked
website security